@article{e5ef5a50227a4bd894beb273e0ffeb0b,
title = "Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis.",
author = "C. Gasparetto and V. Sanchorawala and Snyder, \{R. M.\} and J. Matous and Terebelo, \{H. R.\} and N. Janakiraman and Mapara, \{M. Y.\} and C. Webb and J. Abrams and Zonder, \{J. A.\}",
note = "8024\textasciicircum{} Background: AL amyloidosis is a monoclonal plasma cell disorder with progressive organ dysfunction and short survival. Standard non-transplant AL therapy is melphalan (M) + dexamethasone (D). As adding bortezomib (Bz) to M+ Prednisone improved outcomes in myeloma, we sought to determine if adding Bz to MD improves outcomes in AL.",
year = "2010",
month = may,
day = "20",
doi = "10.1200/JCO.2010.28.15\_SUPPL.8024",
language = "American English",
volume = "28",
journal = "Journal of Clinical Oncology",
}